This is a StreetInsider.com Premium Only Page

Insmed (INSM) – StreetInsider.com Reports

Apr 11, 2024 02:57 AM Insmed (INSM) PT Raised to $40 at Barclays

Apr 5, 2024 07:00 PM These stocks are Wells Fargo's 14 high-conviction ideas for Q2

Apr 1, 2024 05:51 AM Wells Fargo Adds Insmed (INSM) to Q2 '24 Tactical Idea List

Mar 11, 2024 09:34 AM Insmed (INSM) Reports AstraZeneca (AZN) Exercised Rights to Further Develop brensocatib

Feb 26, 2024 04:22 PM UBS Starts Insmed (INSM) at Buy, 'We see ~60% upside to the current share price'

Feb 23, 2024 06:30 AM Insmed (INSM) PT Raised to $40 at BofA Securities

Feb 22, 2024 07:06 AM Insmed (INSM) Misses Q4 EPS by 12c ; Provides Outlook

Feb 15, 2024 03:43 PM Wolfe Research begins coverage on biotech, names Alpine Immune Sciences as Top Pick

Feb 15, 2024 04:49 AM Wolfe Research Starts Insmed (INSM) at Outperform, 'we predict highly favorable risk/reward'

Jan 8, 2024 03:31 AM Insmed (INSM) PT Raised to $37 at Barclays

Dec 7, 2023 04:17 PM Wells Fargo Starts Insmed (INSM) at Overweight

Nov 20, 2023 03:58 AM JPMorgan Reinstates Insmed (INSM) at Overweight

Oct 27, 2023 06:37 AM Insmed (INSM) PT Raised to $35 at Mizuho Securities

Oct 26, 2023 07:34 AM Insmed (INSM) Tops Q3 EPS by 2c ; Offers Guidance

Sep 7, 2023 06:02 AM Insmed (INSM) PT Raised to $42 at Evercore ISI

Sep 6, 2023 09:28 AM Insmed (INSM) PT Raised to $37 at BofA Securities

Sep 6, 2023 07:05 AM Insmed (INSM) PT Raised to $33 at Mizuho Securities

Sep 5, 2023 12:52 PM Insmed (INSM) PT Raised to $52 at Guggenheim

Sep 5, 2023 07:06 AM Insmed (INSM) Reports Positive Topline Data from Phase 3 ARISE study of ARIKAYCE

Aug 4, 2023 08:31 AM Insmed (INSM) PT Raised to $35 at Stifel

Aug 3, 2023 07:32 AM Insmed (INSM) Misses Q2 EPS by 65c, beats revenue, provides guidance

Jul 25, 2023 04:10 PM Guggenheim Starts Insmed (INSM) at Buy

May 19, 2023 04:27 PM Insmed (INSM) Announces Proposed Debt and Share Offering

May 4, 2023 08:10 AM Insmed (INSM) Misses Q1 EPS by 4c ; Offers Guidance

Apr 24, 2023 06:21 AM Insmed (INSM) PT Raised to $35 at BofA Securities

Mar 1, 2023 07:15 AM Insmed (INSM) PT Lowered to $36 at JPMorgan

Feb 24, 2023 08:42 AM Insmed (INSM) PT Lowered to $33 at Stifel

Feb 24, 2023 06:51 AM Insmed (INSM) PT Lowered to $46 at Cantor Fitzgerald

Feb 23, 2023 07:49 AM Insmed (INSM) Misses Q4 EPS by 17c; Offers FY23 ARIKAYCE Revenue Guidance

Feb 21, 2023 07:55 AM Insmed (INSM) PT Lowered to $34 at Stifel

Jan 20, 2023 05:58 AM Insmed (INSM) PT Lowered to $35 at Barclays

Dec 8, 2022 04:16 PM Mizuho Securities Starts Insmed (INSM) at Buy

Dec 7, 2022 05:50 AM Barclays Starts Insmed (INSM) at Overweight

Nov 18, 2022 06:02 AM BofA Securities Starts Insmed (INSM) at Buy

Oct 31, 2022 09:32 AM Insmed (INSM) PT Lowered to $39 at JPMorgan

Oct 31, 2022 06:52 AM Insmed (INSM) PT Lowered to $32 at Evercore ISI

Oct 27, 2022 04:07 PM Insmed (INSM) PT Lowered to $44 at Goldman Sachs

Oct 21, 2022 09:04 AM Insmed (INSM) PT Lowered to $53 at Cowen

Oct 19, 2022 08:50 AM Insmed (INSM) Announces Strategic Financings Totaling $775 Million

Oct 19, 2022 07:04 AM Insmed (INSM) expects global revenue to be approximately $67.7 million for the quarter

Aug 4, 2022 07:35 AM Insmed (INSM) Tops Q2 EPS by 9c

May 23, 2022 08:01 AM Insmed (INSM) Appoints Drayton Wise as Chief Commercial Officer

May 18, 2022 06:10 PM Cantor Fitzgerald Reiterates Overweight Rating, $53 Price Target on Insmed (INSM)

May 18, 2022 05:49 AM Insmed (INSM) Presents New Data from Three Clinical Programs

May 6, 2022 03:47 AM Insmed (INSM) PT Lowered to $40 at Evercore ISI

May 5, 2022 04:42 PM UPDATE: Insmed (INSM) PT Raised to $41 at Stifel

May 5, 2022 03:54 PM Insmed (INSM) PT Lowered to $57 at Credit Suisse

May 5, 2022 07:41 AM Insmed (INSM) Tops Q1 EPS by 8c

Apr 27, 2022 04:43 AM UPDATE: Goldman Sachs Starts Insmed (INSM) at Buy

Feb 17, 2022 04:51 PM Insmed (INSM) PT Slashed to $53 at Cantor Fitzgerald, Lower Sales Forecast for Arikayce and Increased OpEx Weigh In